Akcea Therapeutics Steps Up Commercialization Efforts In Europe
With one rare disease drug already available in Europe, and a second imminent, Akcea’s CEO outlined in a Scrip interview the European plans for this still-youthful US biotech.
With one rare disease drug already available in Europe, and a second imminent, Akcea’s CEO outlined in a Scrip interview the European plans for this still-youthful US biotech.